Aclaris Therapeutics (ACRS) Announces Proposed Public Offering of Common Stock

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. HUMA
3. SPY
4. NAVN
5. USO
6. CHWY
7. cASY
8. SPCX
9. EQPT
10. PCT

Go back to Aclaris Therapeutics (ACRS) Announces Proposed Public Offering of Common Stock

Aclaris Announces Proposed Public Offering of Common Stock

January 19, 2021 4:01 PM EST

WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by Aclaris. Aclaris also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the... More

Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

January 19, 2021 7:00 AM EST

Durable Clinical Activity over 12 Weeks was DemonstratedData Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid ArthritisATI-450, an Investigational Oral MK2 Inhibitor, was Generally Well ToleratedData Support Progression to Phase 2bManagement to Host Conference Call at 8:00 AM ET Today

WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing... More